CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameCD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsInflammationPrimary Immunodeficiency DiseasesFemale Urogenital Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)University Of Pittsburgh
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of PittsburghNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsInflammationPrimary Immunodeficiency DiseasesFemale Urogenital Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A